Krystal Biotech (KRYS) Net Equity Issued and Repurchased (2017 - 2023)
Krystal Biotech (KRYS) posted quarterly Net Equity Issued and Repurchased of $10000.0 for Q4 2023, up 100.25% year-over-year from $4993.7 in Q4 2022, and up 108.2% on a QoQ basis from -$122000.0 in Q3 2023.
Krystal Biotech (KRYS) Net Equity Issued and Repurchased (2017 - 2023) Analysis & Trends
Krystal Biotech has reported Net Equity Issued and Repurchased for 7 years, with the latest figure at $10000.0 in Q4 2023.
- Net Equity Issued and Repurchased for Q4 2023 came in at $10000.0, up 100.25% year-over-year; the trailing twelve-month figure through Dec 2024 was -$112000.0 (down 100.07% YoY), and the FY2023 annual result was $159.7 million, up 451.01% from the prior year.
- Net Equity Issued and Repurchased grew to $10000.0 in Q4 2023, from -$122000.0 in the prior quarter.
- Over five years, Net Equity Issued and Repurchased peaked at $202.1 million in Q4 2021 and troughed at -$3.9 million in Q4 2022.
- A 5-year average of $38.5 million and a median of $1.1 million in 2020 frame the typical range for Net Equity Issued and Repurchased.
- The widest annual swing landed in 2019, when Net Equity Issued and Repurchased soared 2350375.0%; it then tumbled 105.75% in 2023.
- A 5-year view of Net Equity Issued and Repurchased shows it stood at $299000.0 in 2019, then jumped by 157.53% to $770000.0 in 2020, then soared by 26143.12% to $202.1 million in 2021, then slumped by 101.95% to -$3.9 million in 2022, then jumped by 100.25% to $10000.0 in 2023.
- Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $10000.0 in Q4 2023, -$122000.0 in Q3 2023, and $157.6 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Krystal Biotech | 9.83 Bn | 8.99 Bn | 112.79 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 10,000.00 |
| Dec 31, 2023 | 10,000.00 |
| Sep 30, 2023 | -122,000.00 |
| Sep 30, 2023 | -122,000.00 |
| Jun 30, 2023 | 157.62 Mn |
| Jun 30, 2023 | 157.62 Mn |
| Mar 31, 2023 | 2.22 Mn |
| Mar 31, 2023 | 2.22 Mn |
| Dec 31, 2022 | -3.94 Mn |
| Dec 31, 2022 | -3.94 Mn |
| Sep 30, 2022 | 2.12 Mn |
| Sep 30, 2022 | 2.12 Mn |
| Jun 30, 2022 | 30.70 Mn |
| Jun 30, 2022 | 30.70 Mn |
| Mar 31, 2022 | 107,000.00 |
| Mar 31, 2022 | 107,000.00 |
| Dec 31, 2021 | 202.07 Mn |
| Dec 31, 2021 | 202.07 Mn |
| Sep 30, 2021 | 1.51 Mn |
| Sep 30, 2021 | 1.51 Mn |